Literature DB >> 15798490

Irritable bowel syndrome: a syndrome in evolution.

Brian E Lacy1, Ryan De Lee.   

Abstract

As a group, functional gastrointestinal disorders are the most common gastrointestinal disorder seen by both generalists and specialists. These disorders can be frustrating to both patients and physicians as they are usually chronic in nature and difficult to treat. These disorders are associated with frequent healthcare visits, the scheduling of multiple, expensive diagnostic tests, and the use of both over-the-counter and prescription medications. All of these factors lead to a significant economic burden to society. In addition, functional gastrointestinal disorders are associated with a reduction in quality of life for the patient. Irritable bowel syndrome (IBS) is the most common of the functional gastrointestinal disorders. This syndrome has been the focus of a large number of research studies over the past two decades. These studies have resulted in a number of significant changes in our definition of IBS. In addition, these research studies have produced considerable changes in our understanding of the etiology and pathogenesis of IBS. In this section, we will review some of the evolutionary changes that have occurred in IBS. We will discuss how the definition of IBS has changed, consider our evolving strategies to evaluate and diagnose IBS, and finally, provide a brief overview of treatment options for this common disorder.

Entities:  

Mesh:

Year:  2005        PMID: 15798490     DOI: 10.1097/01.mcg.0000156110.69232.bb

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

1.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

2.  Small intestinal bacterial overgrowth: a comprehensive review.

Authors:  Andrew C Dukowicz; Brian E Lacy; Gary M Levine
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-02

3.  Does a self-management program change dietary intake in adults with irritable bowel syndrome?

Authors:  Hsiu-Feng Hsueh; Monica E Jarrett; Kevin C Cain; Robert L Burr; Wimon Deechakawan; Margaret M Heitkemper
Journal:  Gastroenterol Nurs       Date:  2011 Mar-Apr       Impact factor: 0.978

Review 4.  Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment.

Authors:  Carol S North; Barry A Hong; David H Alpers
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

5.  Cost-effectiveness of internet-based cognitive behavior therapy for irritable bowel syndrome: results from a randomized controlled trial.

Authors:  Erik Andersson; Brjánn Ljótsson; Filip Smit; Björn Paxling; Erik Hedman; Nils Lindefors; Gerhard Andersson; Christian Rück
Journal:  BMC Public Health       Date:  2011-04-07       Impact factor: 3.295

6.  Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial.

Authors:  Hugo Wallén; Perjohan Lindfors; Erik Andersson; Erik Hedman-Lagerlöf; Hugo Hesser; Nils Lindefors; Cecilia Svanborg; Brjánn Ljótsson
Journal:  BMC Gastroenterol       Date:  2021-07-13       Impact factor: 3.067

7.  Therapeutic effects of biobran, modified arabinoxylan rice bran, in improving symptoms of diarrhea predominant or mixed type irritable bowel syndrome: a pilot, randomized controlled study.

Authors:  Takeshi Kamiya; Michiko Shikano; Mamoru Tanaka; Keiji Ozeki; Masahide Ebi; Takahito Katano; Shingo Hamano; Hirotaka Nishiwaki; Hironobu Tsukamoto; Tsutomu Mizoshita; Yoshinori Mori; Eiji Kubota; Satoshi Tanida; Hiromi Kataoka; Noriaki Okuda; Takashi Joh
Journal:  Evid Based Complement Alternat Med       Date:  2014-08-05       Impact factor: 2.629

8.  Experience Lived by Iranian Patients with Irritable Bowel Syndrome: Transitory Crisis and Liberation.

Authors:  Zinat Mohebbi; Farkhondeh Sharif; Hamid Peyrovi; Mahnaz Rakhshan; Mahvash Alizade Naini; Ladan Zarshenas
Journal:  Invest Educ Enferm       Date:  2019-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.